|
"楊志新"的相關文件
顯示項目 26-50 / 209 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2016 |
Safety of gefitinib in non-small cell lung cancer treatment
|
Hsiue, Emily Han-Chung; Lee, Jih-Hsiang; Lin, Chia-Chi; Yang, James Chih-Hsin; 林家齊; 楊志新; 李日翔 |
| 國立臺灣大學 |
2016 |
Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
|
Gandhi, L.; Gadgeel, S.; Shaw, A.; Barlesi, F.; Crino, L.; Yang, J. C-H.; Dingemans, A-M. C.; Kim, D-W.; de Marinis, F.; Schulz, M.; Liu, S.; Fish, S.; Kotb, A.; Ou, S-H. I.; 楊志新 |
| 國立臺灣大學 |
2016 |
Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice
|
Liang, Yi-Hsin; Shao, Yu-Yun; Liao, Bin-Chi; Lee, Ho-Sheng; Yang, James Chih-Hsin; Chen, Ho-Min; Chiang, Chun-Ju; Cheng, Ann-Lii; Lai, Mei-Shu; 梁逸歆; 楊志新; 邵幼雲; 廖斌志; 賴美淑; 鄭安理 |
| 國立臺灣大學 |
2016 |
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review
|
Lin, Yen-Ting; Yu, Chong-Jen; Yang, James Chih-Hsin; Shih, Jin-Yuan; 楊志新; 余忠仁; 林奕廷; 林怡岑; 施金元 |
| 國立臺灣大學 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D.; 楊志新 |
| 國立臺灣大學 |
2016 |
Profile of the therascreen (R) EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
|
Hsiue, Emily Han-Chung; Lee, Jih-Hsiang; Lin, Chia-Chi; Yang, James Chih-Hsin; 林家齊; 楊志新; 李日翔 |
| 臺大學術典藏 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.;Yang, J. C. -H.;Park, K.;Kim, J. -H.;Bennouna, J.;Chen, Y. -M.;Chouaid, C.;De Marinis, F.;Feng, J. -F.;Grossi, F.;Kim, D. -W.;Liu, X.;Lu, S.;Strausz, J.;Vinnyk, Y.;Wiewrodt, R.;Zhou, C.;Wang, B.;Chand, V. K.;Planchard, D.; 楊志新; Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. |
| 國立臺灣大學 |
2015 |
High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country
|
Lin, Ching-Hung; Shen, Chen-Yang; Lee, Jih-Hsiang; Huang, Chiun-Sheng; Yang, Chih-Hsin; Kuo, Wen-Hung; Chang, Dwan-Ying; Hsiung, Chia-Ni; Kuo, Kuan-Ting; Chen, Wei-Wu; Chen, I-Chun; Wu, Pei-Fang; Kuo, Sung-Hsin; Chen, Chien-Jen; Lu, Yen-Shen; Cheng, Ann-Lii; 林志弘; 楊志新; 陳偉武; 郭文宏; 盧彥伸; 林璟宏; 陳怡君; 郭冠廷; 郭頌鑫; 吳佩芳; 鄭安理; 黃俊升; 張端瑩; 李日翔; 林季宏 |
| 國立臺灣大學 |
2015 |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai, Tzu-Hsiu; Wu, Shang-Gin; Hsieh, Min-Shu; Yu, Chong-Jen; Yang, James Chih-Hsin; Shih, Jin-Yuan; 楊志新; 余忠仁; 謝明書; 吳尚俊; 蔡子修; 施金元 |
| 國立臺灣大學 |
2015 |
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways
|
Lai, Yi-Hua; Chen, Min-Hsuan; Lin, Sih-Yin; Lin, Sheng-Yi; Wong, Yung-Hao; Yu, Sung-Liang; Chen, Huei-Wen; Yang, Chih-Hsin; Chang, Gee-Chen; Chen, Jeremy J. W.; 楊志新; 俞松良; 陳惠文 |
| 國立臺灣大學 |
2015 |
Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma
|
Liao, Bin-Chi; Shao, Yu-Yun; Chen, Ho-Min; Shau, Wen-Yi; Lin, Zhong-Zhe; Kuo, Raymond Nienchen; Lai, Chiu-Ling; Chen, Kuo-Hsing; Cheng, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 楊志新; 邵幼雲; 廖斌志; 賴美淑; 林宗哲; 鄭安理; 郭年真; 陳國興 |
| 國立臺灣大學 |
2015 |
Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis
|
Hsu, Chia-Lin; Chen, Jen-Hau; Chen, Kuan-Yu; Shih, Jin-Yuan; Yang, James Chih-Hsin; Yu, Chong-Jen; Yang, Pan-Chyr; 楊志新; 楊泮池; 許嘉林; 陳冠宇; 余忠仁; 陳人豪; 施金元 |
| 國立臺灣大學 |
2015 |
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
|
Yang, James Chin-Hsin; Ahn, Myung-Ju; Nakagawa, Kazuhiko; Tamura, Tomohide; Barraclough, Helen; Enatsu, Sotaro; Cheng, Rebecca; Orlando, Mauro; 楊志新 |
| 國立臺灣大學 |
2015 |
First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.
|
Tan, Daniel Shao-Weng; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan; 楊志新 |
| 國立臺灣大學 |
2015 |
How to use afatinib in clinical practice
|
Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
|
Liu, Yi-Nan; Chang, Tzu-Hua; Tsai, Meng-Feng; Wu, Shang-Gin; Tsai, Tzu-Hsiu; Chen, Hsuan-Yu; Yu, Sung-Liang; Yang, James Chih-Hsin; Shih, Jin-Yuan; 楊志新; 俞松良; 吳尚俊; 蔡子修; 施金元 |
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
|
Yang, James Chih-Hsin; Ahn, Myung-Ju; Dickgreber, Nicolas J.; Halmos, Balazs; Hirsh, Vera; Hochmair, Maximilian J.; Levy, Benjamin Philip; De Marinis, Filippo; Mok, Tony; O'Byrne, Kenneth; Okamoto, Isamu; Schuler, Martin H.; Sebastian, Martin; Shah, Riyaz N. H.; Tan, Eng-Huat; Yamamoto, Nobuyuki; Marten, Angela; Massey, Dan; Wind, Sven; Carbone, David Paul; 楊志新 |
| 國立臺灣大學 |
2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|
Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L.; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova, Vera; Hirsh, Vera; Bennouna, Jaafar; Orlov, Sergey; Mok, Tony; Boyer, Michael; Su, Wu-Chou; Lee, Ki Hyeong; Kato, Terufumi; Massey, Dan; Shahidi, Mehdi; Zazulina, Victoria; Sequist, Lecia V.; 楊志新 |
| 國立臺灣大學 |
2015 |
Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial).
|
Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin; 楊志新; 施金元 |
| 國立臺灣大學 |
2015 |
Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
|
Tang, Mei-Chuan; Wu, Mei-Yi; Hwang, Ming-Hung; Chang, Ya-Ting; Huang, Hui-Ju; Lin, Anya Maan-Yuh; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.
|
Yang, James Chih-Hsin; Srimuninnimit, Vichien; Ahn, Myung-Ju; Lin, Chia-Chi; Kim, Sang-We; Tsai, Chun-Ming; Mok, Tony; Orlando, Mauro; Puri, Tarun; Wang, Xin; Park, Keunchil; 林家齊; 楊志新 |
| 國立臺灣大學 |
2015 |
Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis.
|
Liao, Bin-Chi; Lee, Jih-hsiang; Lin, Chia-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin; 林家齊; 楊志新; 廖斌志; 余忠仁; 何肇基; 施金元; 李日翔 |
| 國立臺灣大學 |
2015 |
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
|
Lee, Chee Khoon; Wu, Yi-Long; Ding, Pei Ni; Lord, Sarah J.; Inoue, Akira; Zhou, Caicun; Mitsudomi, Tetsuya; Rosell, Rafael; Pavlakis, Nick; Links, Matthew; Gebski, Val; Gralla, Richard J.; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
Yang, James C-H; Sequist, Lecia V.; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I.; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long; 楊志新; 余忠仁 |
| 國立臺灣大學 |
2015 |
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.
|
Oxnard, Geoffrey R.; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Yu, Helena Alexandra; Saka, Hideo; Horn, Leora; Goto, Koichi; Ohe, Yuichiro; Cantarini, Mireille; Frewer, Paul; Lahn, Michael; Yang, James Chih-Hsin; 楊志新 |
顯示項目 26-50 / 209 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
|
